nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

20.06.2023 | review

ASH 2022—new developments in acute myeloid leukemia

verfasst von: Prof. Dr. Michael Pfeilstöcker

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Summary

Recent years have provided progress for the treatment of acute myeloid leukemia (AML) patients by translating insights from basic research on AML biology into new drugs and concepts. The latest developments presented at the 2022 annual meeting of the American Society of Hematology (ASH) are covered in this review, including discussion of new classifications, treatment of elderly unfit patients, and new approaches towards allogeneic transplantation.

Vorheriger Artikel FlASHback—personal highlights regarding myelodysplastic syndrome from the 2022 ASH meeting

Nächster Artikel ASH highlights 2022—multiple myeloma

Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–19.CrossRefPubMedPubMedCentral

Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28.CrossRefPubMed

Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.CrossRefPubMed

Huber S, Baer C, Hutter S, et al. AML and MDS classification according to who 2022 and international consensus classification: do we invent a babylonian confusion of languages? Blood. 2022;140(Supplement 1):555–6.CrossRef

Song GY, Kim T, Ahn SY, et al. Prognostic predictability of 2022 European Leukemianet (ELN) risk stratification in the real world. Blood. 2022;140(Supplement 1):1018–9.CrossRef

Döhner H, Pratz KW, DiNardo CD, et al. ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with Venetoclax and Azacitidine. Blood. 2022;140(Supplement 1):1441–4.CrossRef

Hernández Sánchez A, Ramiro AV, Strang E, et al. Machine learning allows the identification of new co-mutational patterns with prognostic implications in NPM1 mutated AML—results of the European Harmony Alliance. Blood. 2022;140(Supplement 1):739–42.CrossRef

Pratz KW, Jonas BA, Pullarkat VA, et al. Long-term follow-up of the phase 3 Viale—a clinical trial of Venetoclax plus Azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Blood. 2022;140(Supplement 1):529–31.CrossRef

Willekens C, Chraibi S, Decroocq J, et al. Reduced Venetoclax exposition to seven days of Azacitidine is efficient in treatment-naïve patients with acute myeloid leukemia. Blood. 2022;140(Supplement 1):537–8.CrossRef

10.

Reville PK, Kantarjian H, Borthakur G, et al. Venetoclax added to Cladribine (CLAD) + low dose AraC (LDAC) alternating with Azacitidine (AZA) is highly active as frontline therapy in older patients with newly diagnosed acute Myeloid leukemia in a phase 2 study. Blood. 2022;140(Supplement 1):9041–3.CrossRef

11.

Chua CC, Loo S, Reynolds J, et al. High response and prolonged treatment-free remission after a short-course of modified intensive chemotherapy and Venetoclax in elderly AML: an updated analysis of the caveat trial. Blood. 2022;140(Supplement 1):1708–10.CrossRef

12.

Desikan SP, Konopleva M, Takahashi K, et al. Updated phase IIb results of Venetoclax with FLAG-IDA in relapsed or refractory acute myeloid leukemia. Blood. 2022;140(Supplement 1):534–6.CrossRef

13.

Daver N, Senapati J, Maiti A, et al. Phase I/II study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute Myeloid leukemia (AML) and relapsed/refractory (R/R) AML. Blood. 2022;140(Supplement 1):141–4.CrossRef

14.

Daver N, Montesinos P, Aribi A, et al. Abstr 62 broad activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax triplet in high-risk patients with relapsed/refractory acute Myeloid leukemia (AML). Blood. 2022;140(Supplement 1):145–9.CrossRef

15.

Short N, DiNardo CD, Daver N, et al. Updated results from a phase I/II study of the triplet combination of Azacitidine, Venetoclax and Gilteritinib for patients with FLT3-mutated acute Myeloid leukemia. Blood. 2022;140(Supplement 1):2007–9.CrossRef

16.

Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845–57.CrossRefPubMed

17.

Daver N, Perl AE, Maly J, et al. Venetoclax plus Gilteritinib for FLT3-mutated relapsed/refractory acute Myeloid leukemia. J Clin Oncol. 2022;40(35):4048–59.CrossRefPubMedPubMedCentral

18.

Janssen M, Schmidt C, Bruch PM, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL‑1. Blood. 2022;140(24):2594–610.CrossRefPubMed

19.

Stelljes M, Middeke JM, Bug G, et al. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by Allo-HCT: results from the randomized phase III ASAP trial. Blood. 2022;140(Supplement 1):9–11.CrossRef

Titel: ASH 2022—new developments in acute myeloid leukemia
verfasst von: Prof. Dr. Michael Pfeilstöcker
Publikationsdatum: 20.06.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00896-z

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Assessment of nutritional status using objective and subjective methods in Greek patients with cancer

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

How the long-term follow-up is organized in young adult survivors of childhood cancer

American Society of Hematology meeting update

Head and neck cancer revisited

Long-term survival and follow-up care after cancer in Austria